Pembrolizumab and indoximod for melanoma

Prof Zakharia speaks with ecancer at AACR 2017 about adding indoximod, an IDO inhibitor, to pembrolizumab to treat advanced melanoma. In this interim report of results from 102 patients, he highlights that 52% of all patients respond, and that those figures increase when discounting patients with aggressive ocular melanoma. Compared to phase III single agent studies of pembrolizumab, these results are a marked improvement in response with minimal added toxicity, though Dr Zakharia cautions against direct comparison before further trials conclude.